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Abstract
Headache disorders are considered the second leading cause of years lived with disability
worldwide, and 90% of people have a headache episode at least once a year, thus repre-
senting a relevant public health priority. As the pharmacist is often the first and only point of
reference for people complaining of headache, we carried out a survey in a nationwide sam-
ple of Italian pharmacies, in order to describe the distribution of migraine or non-migraine
type headaches and medicines overuse among people entering pharmacies seeking for
self-medication; and to evaluate the association, in particular of migraine, with socio-demo-
graphic and clinical characteristics, and with the pathway of care followed by the patients. A
14-item questionnaire, including socio-demographic and clinical factors, was administered
by trained pharmacists to subjects who entered a pharmacy requesting self-medication for a
headache attack. The ID Migraine™ Screener was used to classify headache sufferers in
four classes. From June 2016 to January 2017, 4424 people have been interviewed. The
prevalence of definite migraines was 40%, significantly higher among women and less edu-
cated people. About half of all headache sufferers and a third of migraineurs do not consider
their condition as a disease and are not cared by any doctor. Among people seeking self-
medication in pharmacies for acute headache attacks, the rate of definite or probable
migraine is high, and a large percentage of them is not correctly diagnosed and treated. The
pharmacy can be a valuable observatory for the study of headaches, and the first important
step to improve the quality of care delivered to these patients.
Introduction
Headache disorders are considered by The Global Burden of Disease study as the second
leading cause of years lived with disability worldwide [1]. The World Health Organization
declared that headache disorders are ubiquitous, prevalent and disabling but despite this
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they are under-recognized, under-diagnosed and under-treated all over the world [2].
Ninety percent of people have a headache episode at least once a year and 40% are serious or
disabling headaches. Headaches cause a loss of productivity at work, a reduction in social
interactions and a deterioration in the quality of life [2]. Globally, it has a prevalence of 47%
and is the most common neurological syndrome for which people turn to their family doctor
while only 16% consult a neurologist [2]. Recent epidemiological studies have shown that
the phenomenon of migraine may be compared to an iceberg: the top represents correctly
diagnosed cases while the submerged part is made up of those subjects that have never con-
sulted a doctor or that, having done so, have not received a correct diagnosis [3, 4]. Further-
more, in Italy, many migraineurs make a wrong self-diagnosis assuming cervical spine
pathology as the cause [5]. This explains why the majority of migraineurs make use of self-
medication, taking over the counter (OTC) analgesics to treat their headache [6,7]. The lack
of a proper treatment for headache, however, can lead to an overuse of acute pain-relief
medicine and to the medication overuse headache (MOH), an even more disabling chronic
disorder [8,9].
In Europe, the total annual cost of headache amongst adults aged 18–65 years was calcu-
lated, in a study of 2012, at €173 billion [10]. In Italy, among the neurological disorders,
migraine ranked first for direct and indirect costs with a total expenditure amounting to
€ 3.5 billion per year [11]. An Italian study conducted on 135 patients with MOH, demon-
strated that the direct costs, calculated by medications for acute treatment and prophylaxis,
diagnostic procedures, visits, complementary treatments, informal care, were around 415
€/month per person; indirect costs were 530 €/month, and were mostly due to presenteeism
(350 €, 66.3%), i.e. days worked with headache, rather than to absenteeism, lost workdays
(160 €, 33.7%) [12]. Thus, headaches in general and migraines in particular represent not
only an enormous limitation for the affected person, but a problem for the entire commu-
nity [13].
The pharmacist is often the first and only point of reference for the patient complaining of
headache, and participates in the management of this widespread disorder. He/she should be
able to understand the problem raised by the patient, recommend the most appropriate symp-
tomatic treatment and, if necessary, refer the patient to a general practitioner or a specialist.
With proper training, the community pharmacist could be responsible for identifying patients
suffering from suspected migraine symptoms that have not been diagnosed, owing to poor
awareness about the problem and lack of specialist advice [14]. Community pharmacies are
also the ideal site where the risks associated with inappropriate self-medication could be pre-
vented. Community pharmacists are strategically positioned as they have a clear overview of
the medications taken by a patient, whether prescribed by a physician or purchased directly
[15].
Considering the potential role of community pharmacists, and his/her strategical role as
first contact with headache sufferers, a preliminary study was carried out in Piedmont in
2014, with the objective of analyzing the patterns of use of drugs in subjects who entered a
pharmacy requesting OTC medications in order to treat a headache attack [16]. Thanks to the
findings of that study, both from an epidemiological perspective and a public health policy
point of view [16, 17], the decision was taken to expand the scale of the model to a national
level. The detailed protocol of the national survey has already been reported [18]. The objec-
tives of the present paper are to describe the distribution of migraine or non-migraine type
headaches and medicines overuse among people entering pharmacies seeking for self-medica-
tion; and to evaluate the association, in particular of migraine, with socio-demographic and
clinical characteristics, and with the pathway of care followed by the patients.
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Materials and methods
The study was designed as a cross-sectional survey based on face-to-face interviews using ques-
tionnaires drawn up by experts and based on the scientific literature. Briefly, the questionnaire,
reported in Fig 1, covered the following points: the socio-economic situation of the recruited
Fig 1. Questionnaire.
https://doi.org/10.1371/journal.pone.0211191.g001
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subjects; the ID Migraine screener test (ID-MS) [19,20]; the frequency of attacks, the drugs
usually taken and the healthcare professional, if any, responsible for the management of the
subject’s headache.
Given the nature of the centres responsible for recruiting the subjects (community pharma-
cies), a single national online training course was employed to prepare the pharmacists in
order to ensure that the data were collected as homogeneously as possible. At the end of the
training course, each pharmacist had to pass a final test before being enrolled in the project.
Pharmacists were selected on a voluntary basis, and did not receive any payment for their par-
ticipation in the survey.
The questionnaire, was administered to subjects who entered a pharmacy requesting self-
medication for a headache attack, from June 2016 to January 2017. The subjects were recruited
at a maximum rate of five patients per pharmacy per month. [18]
Age at enrolment was categorized in three levels: less than 30 years, 30–54 years and more
than 54 years. Educational level was measured by means of the maximum attained classifica-
tion and classified according to the International standard classification [21] in three levels:
low, including people up to the completion of lower secondary school (ISCED 0–2); medium,
including higher secondary school diplomas (ISCED 3); and high, with any university degree
(ISCED 5–6).
The clinical section included information about symptoms, occurrence and severity of
headaches, together with the items of the ID-MS, resulting in a four-level variable that classifies
patients as suffering from definite migraine, probable migraine, unlikely migraine, or other
headaches [19, 20]. The variable “Number of days with headache in the last three months” was
categorized in two ways:
1. 0–44 days and�45 days in accordance with the criteria laid down by the International
Headache Society (IHS) classification [22] to distinguish episodic migraine (EM) (<15 days
per month) from chronic migraine (CM) (�15 days per month);
2. <11days, 11–29 days, 30–60 days e >60 days in line with the time limits recently recom-
mended by Manzoni et al [23] in order to distinguish respectively: infrequent EM (�3days
per month), frequent EM (>3 but<10 days per month), very frequent migraine—or CM-
(�10 but�20 days per month) and transformed migraine (TM) (>20 days per month).
People who declared to take pain medications for more than 10 days a month were classi-
fied as medicines overusers (MOs).
Finally, as for pathway of care, patients were asked which medicines were usually taken in
case of an acute attack and whether they were monitored by a professional for the treatment of
headache. More details on the protocol of the survey are reported elsewhere [18].
To describe the association of age, pathway of care and clinical information with the type of
headache, we computed conditional relative frequencies and related chi-square p-values, strat-
ified by gender. The Monte-Carlo exact test was applied if the cells with expected conjoint fre-
quencies lower than 5 were more than 20%. Statistical analyses were carried out using the SAS
software (version 9.2).
Patient involvement
The study was designed in order to describe the distribution of migraine or non-migraine type
headaches and medicines overuse among people seeking for self-medication, and to evaluate
its association with individual characteristics and with the pathway of care followed by the
patients. The study was approved by the national association of cephalalgic patients. The study
was also approved and then financed by the Federation of the Orders of Italian Pharmacists
Self-medication for migraine in Italy
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(FOFI). Approval by an ethics committee was not required because the subjects participated in
the study on a voluntary basis and they were informed on the characteristics and the purpose
of the study. The questionnaire was anonymous, personal data were not collected and there is
no way to trace back the answers to a specific responder.
Results
The development of the study at a national level expanded the number of participating phar-
macists to 610, operating in 514 community pharmacies situated in 19 out of the 20 Italian
regions. Out of 610 trained pharmacists, 445 collected at least one questionnaire and partici-
pated in this survey; overall, 4424 questionnaires had been correctly completed.
The prevalence of migraine and headache according to the ID-MS classification, by socio-
demographic characteristics is summarized in Table 1. The study population included mostly
women (74%), highly educated people (only 25% in the lowest level), residing in the North of
Italy (84%), and with a mean age of 45 years. Among people asking for self-medication because
of headache, 40% has a definite migraine and 31% a probable migraine, while the remaining
30% is unlikely to have a migraine or has other forms of headaches.
The ID-MS shows a strong association with gender: almost half of the women (45%) were
classified as definite migraine vs. only a quarter of men (26%), while the percentage of men
with other types of headaches was twice that of women (14% vs. 7%). The overall ratio of
females to males equals 2.8:1, but it is 4.9:1 among subjects with definite migraine and 1.4:1 for
non-migraine sufferers.
Within the sample, the rate of definite migraines was significantly higher among the two
lower educational levels than among people with university qualifications (44% and 42% vs.
35%); there were slightly more other headaches in people living in the North compared to the
rest of Italy (9% vs. 6%). Mean age was homogeneously distributed across the classes of
migraine according to the ID-MS classification.
Table 1. Prevalence (%) of migraine according to the ID-MS classification by socio-demographic characteristics.
Socio-demographic
characteristics
migraine classes according to the ID-MS classification Total p-value §
other headaches
(N = 389)
unlikely migraine
(N = 898)
probable migraine
(N = 1372)
definite migraine
(N = 1765)
% % % % N %
Gender
Female 7.0 18.1 29.9 45.0 3265 73.8 <0.0001�
Male 13.7 26.4 34.3 25.6 1159 26.2
Educational level
Low 8.2 20.1 28.3 43.4 1112 25.1 0,0001�
Medium 8.9 18.7 30.7 41.7 1900 42.9
High 9.1 22.7 33.5 34.7 1412 31.9
Residence area
North 9.3 19.6 31.3 39.8 3726 84.2 0,004�
Center, South and Isles 6.2 24.1 29.4 40.4 698 15.8
Age in years mean
value
mean 46.0 45.5 44.6 45.1 45.1 0.21
Total (%) 8.8 20.3 31.0 39.9 4424
§ p-values referred to the chi-square or Monte-Carlo exact tests on the distribution of the socio-demographic characteristics across all ID-MS classes
� Statistically significant
https://doi.org/10.1371/journal.pone.0211191.t001
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When looking at men and women separately (Table 2), a chronic headache (at least 45
headache days over the previous three months) is reported in 5.4% of men (n = 63) and in
7.9% of women (n = 257) and MOs in 14.9% (n = 173) and 18.8% (n = 613), respectively. Less
than 10% (130 men and 189 women) have had this condition for less than one year, while
about 60% have been affected for at least 10 years (563 men and 2039 women).
Almost all the covariates are significantly associated with the type of headache, except for
age and some types of drugs (as ergot-derivatives, combination drugs and other analgesics). In
particular, a higher duration and frequency of headache (higher number of years and of days
in each month) is associated with higher prevalence of “definite migraine”, as well as a higher
number of drugs. These associations are particularly evident among women. Also MOs were
significantly overrepresented among subjects with definite or probable migraine (76% among
men and 88% among women); only 6.4% of men MOs and 2.4% of women suffered from non-
migraine headaches.
As for therapies, triptans and nonsteroidal anti-inflammatory drug (NSAID) users are
mostly affected by more severe migraines (81% and 70%, respectively among men; 91% and
84% among women), but only 38% of subjects with definite migraine take triptans in order to
block the attack. On the other hand, men use all the other types of drugs independently of the
migraine class, while women with other forms of headaches tend to use only other analgesics.
Headaches classified as probable or definite migraines are more often not resolved by pain
medication, other types of headaches are usually blocked with symptomatic medications.
Finally, about 50% of all patients and 30% of those who suffer from definite migraines do
not believe that headache is a disease and do not require medical care, especially among men.
Indeed, 49% of men and 63% of women who are not cared by any doctor are likely to be seri-
ous migraineurs. Of those who do consult a doctor, half goes to the general practitioner and
the other half is in care with a specialist or at a headache centre. For both genders, the higher
the ID-MS class, the higher the percentage of patients who believe that migraine is a disease
and who are in care by either a physician or a Headache Center.
Discussion
In accordance with other studies [13] we report that women are more likely than men to suffer
from headaches, particularly from migraines. In both genders, there appears to be a trend
towards mainly non-occasional headaches and migraines, existing for a long time and accom-
panied by an important prevalence of chronic headache. Since the epidemiological data
reported in the literature indicate a prevalence of chronic migraine in the general population
of only 2%, must be true that the migraineurs entering a pharmacy and enrolled in this survey
have a relatively severe form of migraine.
Despite the specificity and usefulness of triptans, which have been available on the market
for over 25 years, we found that only one third of severe migraineurs use this class of medica-
tion. This is in line with data from Fisher et al., where it has been reported that almost three
quarters of patients admitted for a preliminary observation at the Headache Outpatient Clinic
had never taken triptans before [24].
It has long been known that the overuse of symptomatic medications can worsen migraine,
until it loses the typical episodic temporal pattern and transform it into a chronic headache
[25]. In this context we can speak of MOs. In our study, approximately one quarter of subjects
with definite migraine declared that they took symptomatic medications at a frequency
deemed to be medication overuse by the criteria in the IHS classification [26]. If we consider
the worsening of the migraine due to medication overuse and the difficulty in detecting
migraineurs who often self-medicate without consulting a doctor, this high percentage of
Self-medication for migraine in Italy
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Table 2. Prevalence (%) of migraine according to the ID-MS classification by gender and clinical characteristics.
Clinical
characteristics
MALE FEMALE
migraine classes migraine classes
other
headaches
N = 159
unlikely
migraine
N = 306
probable
migraine
N = 397
definite
migraine
N = 297
other
headaches
N = 230
unlikely
migraine
N = 592
probable
migraine
N = 975
definite
migraine
N = 1468
N % % % % p-value § N % % % % p-value §
Age
�29 138 11,6 27,5 34,1 26,8 0,67 447 6,7 18,3 33,3 41,6 0,16
30–54 724 13,8 25,7 33,4 27,1 2092 6,5 18,0 29,3 46,2
�55 297 14,5 27,6 36,4 21,5 726 9,0 18,3 29,3 43,4
Number of
years with
headache
<1 130 36,9 31,5 22,3 9,2 <0.0001� 189 20,6 37,0 26,5 15,9 <0.0001�
1–4 268 14,6 30,6 34,3 20,5 537 10,2 25,0 32,6 32,2
5–9 198 11,1 22,7 38,9 27,3 500 6,8 16,8 33,8 42,6
�10 563 8,9 24,5 35,3 31,3 2039 5,0 14,9 28,5 51,6
Number of days with headache in
the last three months
<45 1096 14,2 26,7 34,3 24,7 0,01� 3008 7,3 18,6 30,3 43,9 0,0002�
�45 63 4,8 20,6 33,3 41,3 257 3,9 13,2 25,3 57,6
Number of days with headache in
the last three months
<11 871 15,8 28,6 33,6 21,9 <0.0001� 2153 9,0 20,9 30,5 39,6 <0.0001�
11–29 177 6,8 22,0 35,6 35,6 638 2,8 12,9 29,2 55,2
30–60 74 9,5 13,5 40,5 36,5 333 4,5 11,1 30,0 54,4
>60 37 5,4 21,6 29,7 43,2 141 2,8 15,6 23,4 58,2
Number of
types of
medicines
1 935 15,1 28,2 33,9 22,8 <0.0001� 2531 8,0 20,3 30,9 40,8 <0.0001�
2 197 8,6 18,8 35,5 37,1 620 4,5 11,1 27,9 56,5
�3 27 3,7 18,6 37,0 40,7 114 .0.0 7,9 17,5 74,6
Medication
Overuse
Headache
No 986 15,0 27,9 34,2 22,9 <0.0001� 2652 8,1 20,0 30,8 41,0 <0.0001�
Yes 173 6,4 17,9 34,7 41,0 613 2,4 10,0 25,6 62,0
Type of drug
NSAIDs 272 9,9 20,6 31,6 37,9 <0.0001� 964 3,4 12,6 25,1 58,9 <0.0001�
Ergot-
derivatives
28 7,1 28,6 28,6 35,7 0,5 123 1,6 8,1 23,6 66,7 <0.0001�
Triptans 220 4,1 15,0 33,6 47,3 <0.0001� 855 1,5 7,0 24,9 66,5 <0.0001�
Combination
drugs
82 9,8 20,7 36,6 32,9 0,26 284 2,5 14,1 20,8 62,7 <0.0001�
Other analgesics 197 13,7 22,8 34,0 29,4 0,48 564 6,9 17,6 27,3 48,2 0,35
Pain medication
solved the problem
Yes 613 18,9 32,8 32,0 16,3 <0.0001� 1384 11,8 25,1 32,6 30,6 <0.0001�
Often 360 10,0 19,7 39,4 30,8 1055 3,7 16,0 29,8 50,5
Rarely 128 5,5 16,4 29,7 48,4 538 3,7 8,0 25,8 62,5
No 58 0,0 22,4 36,2 41,4 288 2,8 11,5 24,7 61,1
(Continued)
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migraineurs MO entering a pharmacy is clear evidence of the fundamental importance of this
site as the first point of contact for medicines overuse management.
About half the subjects included in our study believe that their headache is not a disease
and manage their pain by themselves without consulting a medical professional. The migrain-
eurs have a greater awareness of this condition as a disease, and are more likely to be treated
by medical professionals, although a third of subjects with definite migraine does not receive
any medical consultation, thus giving wide space to interventions aimed to improve the quality
and appropriateness of care delivered to these patients. The fact that this condition mainly
affects middle-aged subjects very busy from the working point of view and generally in good
health except for migraine problems, reduces the chance of consulting a doctor. An interesting
study conducted in the US in 1998 [27] indicated that a mere 50% of migraineurs in the gen-
eral population were in care with a doctor. They found, moreover, that even amongst those
who consulted a doctor, the majority either had been misdiagnosed, or had been diagnosed
correctly but were being treated with an inappropriate therapy or, even having been diagnosed
correctly and receiving a correct therapy, had not been going back for regular follow-up exam-
inations. The study arrived at the bitter conclusion that a tiny percentage of migraineurs (6%)
were managed appropriately. The higher percentage of migraineurs consulting a doctor found
by our study is probably due to the fact that not the general population was analysed but sub-
jects were entered into a pharmacy looking for pain relief and, therefore, affected by a more
severe form of migraine.
To sum up, the results of our investigation highlight that females make up the great major-
ity of subjects entering a pharmacy seeking pain relief; approximately 40% of all cases were
subjects with definite migraine and for many of them the migraine symptoms had been pres-
ent for many years and with frequent attacks, which did not always respond to symptomatic
therapies. About half of headache sufferers and about a third of migraineurs do not consider
their condition as a disease and tend to self-medicate, which leads to inappropriate treatment
of the condition.
Table 2. (Continued)
Clinical
characteristics
MALE FEMALE
migraine classes migraine classes
other
headaches
N = 159
unlikely
migraine
N = 306
probable
migraine
N = 397
definite
migraine
N = 297
other
headaches
N = 230
unlikely
migraine
N = 592
probable
migraine
N = 975
definite
migraine
N = 1468
The headache is
a disease
No 677 20,4 33,1 34,4 12,1 <0.0001� 1545 12,4 26,9 33,7 27,0 <0.0001�
Yes 482 4,4 17,0 34,0 44,6 1720 2,2 10,3 26,4 61,1
Who takes care
of the patient
Nobody 676 17,9 32,7 32,5 16,9 <0.0001� 1547 10,9 26,2 32,6 30,3 <0.0001�
General
practitioner
318 8,2 18,6 39,3 34,0 <0.0001� 1030 4,2 12,1 27,6 56,1 <0.0001�
Specialist 135 8,1 12,6 35,6 43,7 <0.0001� 533 2,8 10,1 25,9 61,2 <0.0001�
Headache
Center
82 3,7 20,7 32,9 42,7 0,0005� 365 2,7 5,5 24,1 67,7 <0.0001�
§ p-values referred to the chi-square or Monte-Carlo exact tests on the distribution of the clinical characteristics across all ID-MS classes
� Statistically significant
https://doi.org/10.1371/journal.pone.0211191.t002
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A limit of our study is that the participating pharmacists were enrolled into the study on a
volunteer basis, and are not a representative sample of the Italian population of pharmacists, as
the rate of participation was much higher in Northern regions of Italy compared to Central or
Southern. Consequently, patients interviewed cannot be considered as representative of the
Italian population seeking for self medication in a pharmacy. Unfortunately, we cannot esti-
mate the magnitude of this source of bias, as there are no available data to compare the charac-
teristics of population entering in pharmacy with the general population. On the other hand,
the fact that all interviewing pharmacists were volunteer and underwent a formal training in
interviewing headache suffering customers should ensure a high level of quality of data
collected.
An original contribution of our work is that we showed the strength of the pharmacies as
epidemiological sentinels, given their capillary network on the field, and their contact with a
wide range of users. This allows any pharmacy-based study to develop a snapshot close to the
real-life situation and far more accurate than that obtained from data based in specialist cen-
tres, enabling a choice of clinical strategies that are coherent with the real needs of the local
population.
Conclusion
The pharmacy can be not only a valuable observatory for the study of headaches, but can also
represent, through the counselling that a formed pharmacist might give, the first important
step in seeking to build a good management relationship for subjects with headache, especially
so for undiagnosed migraineurs; their referral in the first instance to the general practitioner
and then to specialists and headache centres, may prevent the onset of chronic migraine and
medication overuse headache.
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